Anagenics Limited · ASX:AN1
Anagenics — Cellmid — Shareholder Meeting (November 2010)
10 slides from Anagenics's shareholder meeting presentation, Nov 3, 2010
Slide 1: Cellmid Limited
Cellmid Limited Maria Halasz Chief Executive Officer 3 November 2010
Slide 2: Business
Business CELLMID (CDY) Midkine company Di Diagnostics i Th Therapeutics i Lif Lifestyle l Out‐licensing In‐house MK Protein MK Antibodies MK Protein • By indication • CK3000 (screen) • CAMI103 (AMI) • CMS101 (Multiple) • CGRO106 (hair growth) • Non-exclusive • CAN105 (vet) • Protein or genomics
Slide 3: Investment highlights
Investment highlights • Multiple revenue source • Cancer diagnostic licenses • Cancer diagnostic in‐house products • Antibody therapeutics • Midkine protein therapeutics • Cosmeceuticals • Reduced risk • Diagnostic and therapeutic products around the same target • Multiple partnership opportunities
Slide 4: Achievements since 2009 AGM
Achievements since 2009 AGM • Dec 2009 Raised $3.63M in a private placement • Feb 2010 Completed first antibody production • March 2010 Signed collaboration for heart attack program with Pharmahungary • A il 2010 April Si d research Signed h agreement with i hKKumamoto University for CK3000 cancer s
Slide 5: Cellmid's MK ELISA
Cellmid’ss MK ELISA Cellmid • Validation of the MK ELISA is complete • Cellmid’s first product (35 kits in inventory)
Slide 6: MK ELISA: Performance
MK ELISA: Performance • Limit of detection is 8pg/ml; well within the range of healthy serum MK levels of 0‐300pg/ml 0 300pg/ml • Precise measurement with inter‐assay CV <25% • Accurate with a recovery range of between 75% and 125% • Highly specific with no cross‐reactivity to pleiotrophin or other
Slide 7: Programs for 2011
Programs for 2011 Diagnostics Therapeutics Cosmeceuticals O li Out‐licensing i I h In‐house MK Antibodies A tib di MK Protein P t i • By indication • CK3000 Select lead candidate • AMI • Alopecia • Non-exclusive • Canine Cancer Humanise lead ADVANGEN • Protein or In vivo disease models INTERNATIONAL
Slide 8: Upcoming milestones
Upcoming milestones • Launch the Advangen range of hair loss prevention products – 4Q2010 • Complete veterinary cancer diagnostic trials ‐ 2Q2011 • Complete stages 3‐4 of AMI pre‐clinical trials in preparation for IND – 3Q2011 • Efficacy trials on single dose • Whole body retention studies • Complet
Slide 9: Board and management
Board and management • David King (Chairman) • Maria Halasz l (CEO ( and d Managing Director)) • Robin Beaumont (Non‐executive Director) • Koichiro Koike (Non‐executive Director) • Darren Jones (Head of Product Development) • Nicholas Falzon (Company Secretary)
Slide 10: Thank you
Thank you Maria Halasz Chief Executive Officer E: halasz@cellmid.com.au T: +61 2 9299 0311 www.cellmid.com.au